| 3.93 -0.11 (-2.72%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.26 | 1-year : | 6.92 |
| Resists | First : | 4.51 | Second : | 5.92 |
| Pivot price | 4.36 |
|||
| Supports | First : | 2.22 | Second : | 1.84 |
| MAs | MA(5) : | 4.03 |
MA(20) : | 4.12  |
| MA(100) : | 2.88 |
MA(250) : | 2.9 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 17.3 |
D(3) : | 27.8 |
| RSI | RSI(14): 52.6 |
|||
| 52-week | High : | 5.92 | Low : | 1.52 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ NTRB ] has closed above bottom band by 16.7%. Bollinger Bands are 39.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.39 - 4.42 | 4.42 - 4.45 |
| Low: | 3.86 - 3.88 | 3.88 - 3.91 |
| Close: | 3.89 - 3.93 | 3.93 - 3.97 |
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Mon, 01 Apr 2024
What is the Market's View on Nutriband Inc (NTRB) Stock's Price and Volume Trends Monday? - InvestorsObserver
Sun, 31 Mar 2024
Is Nutriband (NASDAQ:NTRB) A Risky Investment? - Simply Wall St
Wed, 27 Mar 2024
Does Nutriband Inc (NTRB) Have What it Takes to be in Your Portfolio Wednesday? - InvestorsObserver
Tue, 26 Mar 2024
NTRB Stock Quote Price and Forecast - CNN
Tue, 26 Mar 2024
Can Nutriband Inc (NTRB) Stock Rise to the Top of Healthcare Sector Tuesday? - InvestorsObserver
Fri, 26 Jan 2024
Nutriband CEO Publishes Letter to Shareholders - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 8 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 52.3 (%) |
| Held by Institutions | 2.5 (%) |
| Shares Short | 36 (K) |
| Shares Short P.Month | 6 (K) |
| EPS | -0.68 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.73 |
| Profit Margin | -253.1 % |
| Operating Margin | -402.9 % |
| Return on Assets (ttm) | -32.1 % |
| Return on Equity (ttm) | -68.5 % |
| Qtrly Rev. Growth | -30.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.24 |
| EBITDA (p.s.) | -0.55 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -5.87 |
| PEG Ratio | 0 |
| Price to Book value | 5.38 |
| Price to Sales | 15.9 |
| Price to Cash Flow | -9.19 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|